In this study, the investigators will explore Atipamezole & caffeine's ability to facilitate the emergence from anesthesia. Each subject will visit UChicago 4 times. The first time for informed consent. The second time for a complete physical exam to ensure that the subjects are healthy. Then there are 2 sedation sessions. Subjects get an honorarium for each sedation session.

Start Date01 May 2023

Sponsor / Collaborator

The University of Chicago

NCT01435213 / CompletedPhase 1

Competition With Striatal [11C]ORM-13070 Binding by Atipamezole and Endogenous Noradrenaline - a PET Study in Healthy Human Subjects

The purpose of this study is to validate [11C]ORM-13070 as an alpha2C-adrenoceptor imaging agent for human positron emission tomography (PET) studies of brain alpha2C-adrenoceptor occupancy.

Start Date01 Sep 2011

Sponsor / Collaborator

University of Turku

[+1]

100 Clinical Results associated with Atipamezole

100 Translational Medicine associated with Atipamezole

100 Patents (Medical) associated with Atipamezole

979

Literatures (Medical) associated with Atipamezole

01 Nov 2024·VETERINARY ANAESTHESIA AND ANALGESIA

Correlation, agreement and concordance of cardiac output estimated by transthoracic ultrasound and transesophageal Doppler with pulmonary artery thermodilution in anesthetized cats

Article

Author: Pypendop, Bruno H ; Barter, Linda S ; Chohan, Amandeep S ; Barter, Linda S. ; Stern, Joshua A ; Rivas, Victor N. ; Couto Bueno, Melissa ; Chohan, Amandeep S. ; Pypendop, Bruno H. ; Stern, Joshua A. ; Bueno, Melissa Couto ; Rivas, Victor N

OBJECTIVE:

To characterize the correlation, agreement and concordance of cardiac output (CO) measured with transthoracic ultrasound and the correlation and concordance of aortic blood flow (ABF) minute distance (MD) measured by transesophageal Doppler with CO measured by pulmonary artery thermodilution (PATD) in cats.

STUDY DESIGN:

Experimental study.

ANIMALS:

A group of six healthy male neutered cats, aged 2-8 years and weighing 5.3 ± 0.3 kg.

METHODS:

Cats were anesthetized with isoflurane in oxygen. CO was measured by PATD (CO_PATD) and transthoracic echocardiography (CO_ECHO). ABF MD was measured using an esophageal Doppler flow probe aligned with descending ABF. All measurements were made under three conditions: dexmedetomidine (20 μg kg^-1) intravenously; atipamezole (200 μg kg^-1) intramuscularly and atropine (20 μg kg^-1) intravenously as needed to achieve a minimum heart rate of 140 beats minute^-1; and dopamine (20 μg kg^-1 minute^-1) intravenously in that order. Correlation between CO_PATD and CO_ECHO, and CO_PATD and Doppler MD was evaluated using repeated measures correlation. Agreement between CO_PATD and CO_ECHO was evaluated using Bland-Altman method. Differences between consecutive pairs of CO measurements were calculated for concordance analysis.

RESULTS:

Correlation between CO_PATD and CO_ECHO and between CO_PATD and MD was significant (p < 0.001), with correlation coefficients greater than 0.92. A bias of > 27% and upper limits of agreement of 66% were found between CO_PATD and CO_ECHO. Concordance rate with CO_PATD was 76-80% for CO_ECHO and 72% for MD.

CONCLUSIONS AND CLINICAL RELEVANCE:

Echocardiographic methods for the measurement of CO showed poor agreement and concordance with PATD. MD showed poor concordance with PATD. As such, these methods cannot be used as an alternative to PATD nor can they appropriately track changes in CO in anesthetized cats.

25 Oct 2024·JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION

Intramuscular injection of a commercially available medetomidine–vatinoxan hydrochloride mixture produces reliable sedation in sheep and goats with varying cardiopulmonary effects

Article

Author: Cremer, Jeannette ; Kuehr, Alaina A. ; Liu, Chin-Chi ; Benton-Levith, Elizabeth J. ; Muir, Andrew J. T. ; Scully, Clare M.

Abstract:

OBJECTIVE:

To evaluate the sedation quality of an IM injection of a commercially available medetomidine-vatinoxan combination (ZEN) in healthy goats and sheep and discern species differences in cardiopulmonary parameters.

METHODS:

10 apparently healthy adult university-owned research Black Bengal–crossbreed goats and 10 adult Gulf Coast native and Katahdin sheep were enrolled in this prospective experimental study from June 27 to July 27, 2023. All animals were sedated on 1 occasion with 0.06 mL of ZEN/kg, IM (0.03 mg of medetomidine/kg and 0.6 mg of vatinoxan hydrochloride/kg). Cardiopulmonary variables including heart rate, arterial blood pressure, and arterial blood gas parameters were recorded along with sedation depth and duration. Any animals still sedated after 150 minutes received 0.01 mg of atipamezole/kg.

RESULTS:

The mean ± SD of the total sedation time for sheep and goats was 102.80 ± 10.90 minutes and 133.50 ± 32.63 minutes, respectively. Profound reliable sedation was achieved in all but 1 animal. Hypoxemia was observed in sheep and goats (11 of 20 animals total). Hypotension was seen in 3 of 10 goats.

CONCLUSIONS:

In sheep and goats, ZEN at 0.06 mL/kg, IM, caused profound sedation. Total sedation time was significantly longer in goats than in sheep.

CLINICAL RELEVANCE:

In the presence of oxygen supplementation, ZEN at 0.06 mL/kg, IM, may be an acceptable sedation choice for apparently healthy Gulf Coast native and Katahdin sheep, but not goats; however, preexisting hypokalemia or pulmonary disease are contraindications for the use of ZEN in sheep.

01 Oct 2024·Journal of the American Association for Laboratory Animal Science

General Anesthesia Induced by a Combination of Medetomidine/Vatinoxan with Ketamine and Buprenorphine-ER in C57BL/6J Mice (Mus musculus)

Article

Author: Franco, Benjamin ; Jampachairsi, Katechan ; Huss, Monika ; Casey, Kerriann ; Tien, Krystal ; Alamaw, Eden D ; Pacharinsak, Cholawat

Abstract:

Medetomidine/vatinoxan (Zenalpha®) is a novel anesthetic combination used as a sedative and analgesic in dogs. Vatinoxan minimizes adverse cardiopulmonary effects associated with medetomidine administration while preserving sedation and analgesia. In this study, we evaluated the clinical safety and efficacy of 3 dosage combinations of Zenalpha with ketamine and buprenorphine extended release (ER) as compared with xylazine with ketamine and buprenorphine-ER for anesthesia of C57BL/6J mice. We hypothesized that anesthesia with 0.5 mg/kg of Zenalpha would more reliably provide a surgical anesthetic plane, lower mortality, and fewer adverse physiologic effects as compared with anesthesia with 8 mg/kg of xylazine. Ten-week-old male and female C57BL/6J mice were randomly administered 1 of 4 anesthetic cocktails subcutaneously: ketamine (80 mg/kg) and buprenorphine-ER (0.5 mg/kg) with 1) xylazine (8 mg/kg; XKB); 2) Zenalpha (0.25 mg/kg; ZKB/0.25); 3) Zenalpha (0.5 mg/kg; ZKB/0.5); or 4) Zenalpha (1.0 mg/kg; ZKB/1.0). Following drug administration, we assessed the anesthesia induction time by measuring the time to loss of righting reflex and loss of paw withdrawal reflex (PWR). Upon reaching a loss of righting reflex, physiologic parameters including heart rate, respiratory rate, oxygen saturation, indirect mean arterial blood pressure, body temperature, jaw tone, and skin color were monitored every 5 min. Thirty minutes after anesthetic drug administration (TA), atipamezole (1 mg/kg SC) was administered. Recovery time was determined through time until return of PWR, righting reflex, and ambulation. Mice were monitored for 3 d postanesthesia. Results included: 1) ZKB anesthesia caused loss of PWR in a dose-dependent manner; 2) physiologic parameters were similar between XKB and ZKB mice by TA in 100% O2; 3) ZKB groups took longer to recover and had a 20% to 30% mortality rate in the mid-to-high dosage groups. We conclude that anesthesia with 0.5 mg/kg of Zenalpha more reliably produced a surgical anesthetic plane but also led to decreased mean arterial pressure and increased mortality as compared with anesthesia with 8 mg/kg of xylazine. We recommend using Zenalpha (0.25 to 1.0 mg/kg) with 80 mg/kg ketamine and 0.5 mg/kg buprenorphine-ER to provide general anesthesia in C57BL/6 mice, along with supplemental 100% oxygen and atipamezole.

News (Medical) associated with Atipamezole

15 Nov 2023

·www.sciencedaily.com

Pulling the plug on brain injury: Manipulating fluid flows could save lives, improve recovery post-TBI

New research shows that a cocktail of drugs already approved to treat high blood pressure quickly reduces brain swelling and improves outcomes in animal models of brain injury. Cerebral edema, the dangerous brain swelling that occurs after traumatic brain injury (TBI), can increase risk of death tenfold and significantly worsen prospects for recovery in brain function. In extreme cases, surgeons will remove a portion of the skull to relieve pressure, but this has significant risks and is not viable for the vast majority of TBI cases. Physicians have very few tools at their disposal that are effective in treating cerebral edema, which is one of the leading causes of in-hospital deaths, and is associated with long-term neurological disability. New research appearing today in the journal Nature could change all that, showing that a cocktail of drugs already approved to treat high blood pressure quickly reduces brain swelling and improves outcomes in animal models of brain injury. "Our research shows that cerebral edema is the consequence of impaired fluid flow through the glymphatic system and its associated lymphatic drainage," said Maiken Nedergaard, MD, DMSc, co-director of the University of Rochester Center for Translational Neuromedicine and senior author of the study. "This impairment is under adrenergic control, and can therefore be rescued pharmacologically by broadly inhibiting adrenergic receptors. Because these drugs are already being used clinically and have observed neurological benefits, there is the potential to move quickly to clinical studies to confirm these findings." Manipulating fluid flows in the brain to release post-TBI brain pressure The glymphatic system was first described by Nedergaard's lab in 2012 as the brain's unique waste removal process. Since then, a growing understanding of the mechanics of the system-aided by advanced imaging technologies and AI-driven models of fluid dynamics -- has allowed researchers to better predict and manipulate the movement of cerebrospinal fluid (CSF) in the central nervous system. This research has opened new possibilities to treat Alzheimer's and other neurological disorders and more effectively deliver and distribute drugs in the central and peripheral nervous system, including the inner ear. The new study points to the potential to repurpose the glymphatic system to act as an emergency pressure release valve. Cerebral edema is a common consequence of moderate and severe cases of TBI. "In other parts of the body, edema helps with tissue repair, but because of the skull, the brain has limited capacity for expansion. As a result, pressure increases, blood supply decreases, and debris and toxic proteins are trapped at the injury site, compounding the damage and impairing recovery," said Rashad Hussain, PhD, an assistant professor in the Center for Translational Neuromedicine and first author of the study. One of the main triggers of cerebral edema is noradrenaline, a neurotransmitter that floods the brain immediately after TBI. Noradrenaline is typically associated with the flight-or-fight response, but in TBI this "adrenergic storm" impairs the flow of CSF in and out of the brain. The researchers describe how noradrenaline interferes with the function of the glymphatic system. Specifically, it restricts the movement of fluid through the section of the system's plumbing where CSF drains from the brain and flows into the meningeal and cervical lymph nodes in the neck. This observation led the team to speculate whether reopening these gates to the lymph nodes could flush excess CSF from the brain, thereby relieving pressure. Blood pressure medications suppress adrenaline "storm" and restart fluid flow To accomplish this, the team used a cocktail of drugs, including prazosin, atipamezole, and propranolol. This combination of alpha- and beta-blockers collectively suppress the different receptors used by cells to take up noradrenaline. Previous research in Nedergaard's lab has shown that this combination of drugs ramps up the glymphatic system, replicating the level of activity experienced when we sleep, which is when the system is most efficient in manipulating CSF flow to remove waste. In the new study, the same drug cocktail was administered to mice soon after TBI. Using fluorescent microspheres, the researchers traced CSF originating from the site of the swelling as it exited in bulk from the brain via lymphatic vessel, carrying with it debris from the injury to the lymph nodes. The result was an almost immediate elimination of cerebral edema and a sustained return to normal intracranial pressure in the animals. The treatment resulted significant recovery of cognitive, behavioral, and motor function. "These findings show that the adrenergic storm, the resulting edema and intracranial pressure, and retention of neural debris, can all be reversed by broad adrenergic inhibition, with subsequent improvement in recovery in injured mice," said Nedergaard. The authors point to several clinical studies that demonstrate the safety profiles and observed neurological benefits of these drugs, early indications that this approach could also benefit humans. Atipamezole reduces post-traumatic seizures, prazosin is effective in treating the post-traumatic stress associated with TBI, and beta-blockers reduce in-hospital mortality and improve functional outcome of TBI patients. Additionally, Nedergaard and her colleagues at the University of Copenhagen have shown that individuals who take beta-blockers for hypertension are at lower risk for Alzheimer's. Additional co-authors in the study include: Jeffrey Tifhof, Wei Wang, Arokoruba Cheetham-West, Wei Song, Weiguo Peng, Qian Sun, Sisi Peng, and Doug Kelley with the University of Rochester; Bjorn Sigurdsson and Pia Weikop with the University of Copenhagen; Virginia Pla, Hajime Hirase and Steve Goldman with both with the Universities of Rochester and Copenhagen; Daeyun Kim with the University of Minnesota; Jorge Castorena-Gonzalez with the Tulane University; and Michael Davis with the University of Missouri. The research was supported with funding from the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the National Institute of Neurological Disorders and Stroke, the Burroughs Wellcome Fund, the Joint Programme -- Neurodegenerative Disease Research, the Novo Nordisk Foundation, the Lundbeck Foundation, and the US Army Research Office.

12 Oct 2022

·www.prnewswire.com

Atipamezole Market to Reach US$70 Mn by 2030, Widespread Use in Anesthesis Reversal in Vet Medicine : TMR Study

Rising demand in safe and reliable reversal of sedative effects of dexmedetomidine and medetomidine propelling revenue size in atipamezole market; preference as injectable for dogs hinges on good tolerability Rising need for effective and safe anti-sedative solutions in pets underpins vast potential; pharmaceutical companies expanding online distribution networks to tap into thriving demand in North America WILMINGTON, Del. , Oct. 12, 2022 /PRNewswire/ -- Rising adoption of anti-sedative agents for safe and quick reversal of sedative effects induced by dexmedetomidine and medetomidine in pets is a key pivot for expansion of profitable avenue for companies in atipamezole market. A TMR study on the growth dynamics found that intramuscular route of administration is expected to be largest revenue generator in atipamezole market. The atipamezole market size is projected to reach US$ 70 million by the end of 2030. Growing regulatory approval of atipamezole solutions for injections in pets will spur future market demand for atipamezole market manufacturing. Veterinary hospitals are estimated to tap into the vast demand for atipamezole solutions in dogs and cats and other companion animals. On the other hand, the study authors observed that rise in investments by various pharmaceutical companies on expanding online pharmacies will also propel revenue streams. Get Exclusive PDF Sample Copy of Atipamezole Market – The TMR study found that leading players in atipamezole market are leaning on R&D for unveiling anti-sedation agents with high tolerability and effectiveness in recovery from anesthesia. Furthermore, drug manufacturers are taking initiatives in raising awareness of correct dosage of atipamezole and special precautions that pet owners and veterinarians need to exercise while administering the injections. Key Findings of Atipamezole Market Study Use as Anti-sedative Agents in Dogs and Cats Underpins Abundant Opportunities: Growing adoption of atipamezole in anti-sedative agents in dogs and cats is generating substantial growth opportunities for companies in the market. Especially in case of health dogs, the injections have demonstrated good tolerability, hence stoking the popularity of products. Educating clinicians of the contraindications will boost the outlook of the atipamezole market, opined the study. R&D on Enhancing Tolerability and Safety of Atipamezole Solutions for Reversal of Medetomidine-Induced Sedation: Ongoing clinical studies and R&D by pharmaceutical companies will pave the way for increasing the tolerability and safety of anesthetic reversal agents. Stridently, the efforts will lead to new revenue streams for firms in the atipamezole market. Massive Research Potential in Sleep Disorder Medications in Adults: Growing demand for medications for insomnia and sleep disorders is creating an incredible revenue potential in atipamezole market. Prevalence of sleep disorders in adults is catalyzing research on ant-sedative agents. Ask for References – Atipamezole Market: Key Drivers Growing spending on pet care in conjunction with growing ownership of pets in developing and developed regions is a key driver of atipamezole market. Of note, ongoing clinical trials pertaining to medications that address complications of prolonged anesthesia in wide variety of species in veterinary medicine is likely to create tremendous lucrative opportunity for pharmaceutical companies. R&D in sleep-inducing drugs for humans holds a massive potential, pivoting on the need for reducing prevalence of insomnia, will open up several new growth frontiers in atipamezole market. Atipamezole Market: Regional Growth Dynamics North America held a major share of the global atipamezole market in 2019. Rise in pet ownership over the past few years coupled with improving infrastructure of veterinary hospitals for companion animals has created massive revenue potential. In addition, rising spending on pet care in the U.S. has generated substantial lucrative demand for ant-sedative products in the region, thereby stirring the commercialization of atipamezole ingredients. Rise in demand for quality animal healthcare services is bolstering the prospects of the atipamezole market in North America. Atipamezole Market: Competition Landscape Multinational pharmaceutical companies in atipamezole market are reaping substantial revenue gains on the back of product approvals by regulatory agencies in various geographies. Key players are keenly expanding their product portfolio. Some of them are Troy Laboratories Pty Ltd, Forte Healthcare Ltd., Chanelle Pharma Group, Vetoquinol UK Ltd, Jurox Pty Limited, Orion Corporation, Modern Veterinary Therapeutics, and Merck & Co., Inc. Make an Enquiry Before Buying – Atipamezole Market Segmentation Application Anti-sedative Antitoxic (Off-label Use) Route of Administration Intramuscular Intravenous Others Animal Type Dogs Cats Others Distribution Channel Veterinary Hospitals Retail Pharmacies Online Pharmacies Region North America Europe Asia Pacific Latin America Middle East & Africa Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research: Anticoagulant Reversal Drugs Market: The global anticoagulant reversal drugs market is anticipated to reach more than US$ 2.3 Bn by the end of 2031 at a CAGR of 11.3% from 2022 to 2031. Macular Degeneration Treatment Market: The global macular degeneration treatment market is anticipated to reach more than US$ 21.1 Bn by the end of 2031 at a CAGR of 8.8% from 2022 to 2031. PET Radiotracer Market: The global PET radiotracer market is anticipated to reach more than US$ 3.2 Bn by the end of 2031 at a CAGR of 8.5% from 2022 to 2031. Gemcitabine HCL Market: The global gemcitabine HCl market is anticipated to reach more than US$ 1.3 Bn by 2031 at a CAGR of 7.8% from 2022 to 2031. Homeopathic Products Market: The global homeopathic products market is anticipated to reach more than US$ 32.4 Bn by the end of 2031 at a CAGR of 11.6% from 2022 to 2031. Pain Management Therapeutics Market: The global pain management therapeutics market is anticipated to reach more than US$ 98.0 Bn by the end of 2031 at a CAGR of 2.9% from 2022 to 2031. Peptide Therapeutics Market: The global peptide therapeutics market is anticipated to reach more than US$ 91.25 Bn by 2031 at a CAGR of 8.8% from 2022 to 2031. Collagen Peptide & Gelatin Market: The global collagen peptide and gelatin market is anticipated to reach more than US$ 7.8 Bn by the end of 2031 at a CAGR of 5.0% from 2022 to 2031. About Transparency Market Research Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyse information. Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - Contact Rohit Bhisey Transparency Market Research Inc. CORPORATE HEADQUARTER DOWNTOWN, 1000 N. West Street, Suite 1200, Wilmington, Delaware 19801 USA Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Website: Blog: Email: [email protected] Logo: SOURCE Transparency Market Research

100 Deals associated with Atipamezole

External Link

KEGG	Wiki	ATC	Drug Bank
D03002	Atipamezole	-	DB11481

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder, Major	Phase 2	FI	Orion Oyj	-
Parkinson Disease	Preclinical	FI	Orion Oyj	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis